Brief: Active Biotech says CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint

Active Biotech AB publ

08/05/2017 06:45

STOCKHOLM, May 8 (Reuters) - Active Biotech  ACTI.ST : 
     
    * Teva and Active Biotech today announced results from the 
CONCERTO trial in patients with relapsing-remitting 
multiple sclerosis (RRMS) 
    * Says primary endpoint in CONCERTO -- the evaluation 
of laquinimod versus placebo to evaluate the time to Confirmed 
Disability Progression (CDP) after at least 3 months - was not 
met 
 
 (Reporting by Stockholm Newsroom)